Segall Bryant & Hamill LLC raised its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 352.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 157,144 shares of the company's stock after purchasing an additional 122,407 shares during the period. Segall Bryant & Hamill LLC owned approximately 0.55% of Krystal Biotech worth $28,605,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also modified their holdings of the company. Sei Investments Co. lifted its position in Krystal Biotech by 18.9% during the second quarter. Sei Investments Co. now owns 40,115 shares of the company's stock valued at $7,367,000 after purchasing an additional 6,363 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Krystal Biotech by 54.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company's stock worth $117,189,000 after buying an additional 231,255 shares during the last quarter. Shaker Investments LLC OH bought a new stake in shares of Krystal Biotech in the third quarter worth $532,000. Amalgamated Bank increased its position in Krystal Biotech by 937.9% during the second quarter. Amalgamated Bank now owns 7,577 shares of the company's stock valued at $1,391,000 after acquiring an additional 6,847 shares during the last quarter. Finally, Everence Capital Management Inc. bought a new position in Krystal Biotech in the third quarter valued at about $557,000. Institutional investors own 86.29% of the company's stock.
Insider Buying and Selling
In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the sale, the insider now directly owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. This represents a 1.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 14.10% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
A number of research firms recently issued reports on KRYS. Evercore ISI raised their price objective on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an "outperform" rating in a report on Monday, August 12th. Citigroup upped their price objective on Krystal Biotech from $204.00 to $206.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. HC Wainwright reiterated a "buy" rating and set a $221.00 target price on shares of Krystal Biotech in a research report on Tuesday, November 5th. William Blair raised shares of Krystal Biotech to a "strong-buy" rating in a report on Friday, August 30th. Finally, Chardan Capital increased their price objective on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a "buy" rating in a research note on Monday, August 5th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $197.00.
Get Our Latest Research Report on KRYS
Krystal Biotech Stock Performance
Shares of KRYS traded up $0.36 during midday trading on Wednesday, hitting $178.21. 72,646 shares of the company traded hands, compared to its average volume of 327,160. The stock has a market cap of $5.13 billion, a price-to-earnings ratio of 100.48 and a beta of 0.82. The firm has a 50 day moving average of $180.45 and a 200-day moving average of $182.02. Krystal Biotech, Inc. has a 52 week low of $99.00 and a 52 week high of $219.34.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping analysts' consensus estimates of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm had revenue of $83.84 million during the quarter, compared to analysts' expectations of $82.94 million. During the same quarter in the previous year, the business earned ($0.67) EPS. The company's quarterly revenue was up 879.9% on a year-over-year basis. Sell-side analysts predict that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.
About Krystal Biotech
(
Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Further Reading
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
